==== Front
J Fungi (Basel)
J Fungi (Basel)
jof
Journal of Fungi
2309-608X MDPI 

33113935
10.3390/jof6040241
jof-06-00241
Review
Host Defense Peptides as Templates for Antifungal Drug Development
https://orcid.org/0000-0001-6078-3439Basso Virginia 1 Tran Dat Q. 12 https://orcid.org/0000-0002-7987-5779Ouellette André J. 13 https://orcid.org/0000-0002-7152-4739Selsted Michael E. 123* 1 Department of Pathology and Laboratory Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA; Virginia.Basso@med.usc.edu (V.B.); dtran@oryntherapeutics.com (D.Q.T.); aouellet@med.usc.edu (A.J.O.)
2 Oryn Therapeutics, Vacaville, CA 95688, USA
3 Norris Comprehensive Cancer Center of the University of Southern California, Los Angeles, CA 90089, USA
* Correspondence: selsted@med.usc.edu
23 10 2020 
12 2020 
6 4 24103 10 2020 21 10 2020 © 2020 by the authors.2020Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).Current treatment for invasive fungal diseases is limited to three classes of antifungal drugs: azoles, polyenes, and echinocandins. The most recently introduced antifungal class, the echinocandins, was first approved nearly 30 years ago. The limited antifungal drug portfolio is rapidly losing its clinical utility due to the inexorable rise in the incidence of invasive fungal infections and the emergence of multidrug resistant (MDR) fungal pathogens. New antifungal therapeutic agents and novel approaches are desperately needed. Here, we detail attempts to exploit the antifungal and immunoregulatory properties of host defense peptides (HDPs) in the design and evaluation of new antifungal therapeutics and discuss historical limitations and recent advances in this quest.

antifungalshost defense peptidespeptidomimeticsimmunomodulationmultidrug resistancedefensins
==== Body
1. Introduction
Invasive fungal infections are a global health concern, with high rates of incidence and mortality, particularly in immunocompromised patients [1,2,3]. The paucity of antifungal drugs available for treatment of invasive mycoses represents a growing public health vulnerability, as the numbers of immunosuppressed individuals grow with increasing use of cancer chemotherapy, bone marrow and solid organ transplants, and immunosuppressive drugs for treatment of autoimmune disorders. Serious, often life-threatening, mycoses that affect humans are primarily due to only a few genera (Table 1). Candida spp. infections range from mild and superficial to invasive infections with mortality rates of 40% or greater [2]. An estimated 200,000 cases of Aspergillus spp. infections occur annually with invasive disease primarily affecting immunocompromised patients. With treatment, invasive aspergillosis causes death in up to 50% of affected patients, whereas left untreated, as often occurs in developing countries, lethality approaches 100% [1]. Immunocompromised patients are also highly susceptible to cryptococcosis caused by Cryptococcus neoformans and closely related Cryptococcus gattii. Although cryptococcosis is initially a pulmonary infection, in the immunosuppressed patient the organism commonly disseminates systemically to the central nervous system (CNS) causing meningoencephalitis with an estimated 70% mortality [1].

Currently, there are three classes of antifungals: azoles, polyenes, and echinocandins (Table 2). Azoles are the most widely used class of antifungal agents because of their bioavailability as oral and intravenous (i.v.) formulations and their excellent safety profiles. However, some Candida species, such as C. krusei, are intrinsically resistant to fluconazole, the most widely used azole. Fluconazole-resistant isolates are emerging rapidly because azoles are fungistatic which promotes resistance selection with extended use [4,5]. Polyenes have been in use since the 1950s, but their toxicities limit their use to severe infections. The toxicity of amphotericin B (AmpB) is well known, particularly its nephrotoxicity, due to its affinity for and disruption of host cell membranes [6]. Fortunately, lipid-associated and liposomal formulations of AmpB have reduced adverse events associated with its use [6]. Although initially approved nearly 30 years ago, echinocandins are the newest class of antifungals. While usually effective in treatment of candidiasis and aspergillosis [7,8], echinocandins are ineffective against Cryptococcus spp. and endemic mycoses [7].

The public health impact of systemic mycoses is amplified by the increasing incidence of multidrug resistant (MDR) pathogens. Numerous clinical isolates have emerged that are resistant to all three classes of approved antifungals [4,9,10,11,12,13], highlighted by the international spread of MDR C. auris, which is now classified by CDC as a serious threat [14,15]. In the United States alone, systemic mycoses are estimated to cause more than 1.6 million deaths annually [16] with associated treatment costs exceeding USD 7 billion [17]. Accordingly, new efforts are underway to address the growing and worldwide impact of systemic fungal infections, including the development of fungal vaccines and new therapeutic strategies [18,19,20]. Here we discuss the potential of host defense peptides (HDPs) (also long referred to as antimicrobial peptides) as bioinspired templates for new agents to treat invasive fungal infections. While antimicrobial peptides are expressed by nearly all life forms, the primary focus of this review will be on antifungal HDPs expressed as elements of the mammalian immune system.

2. Mammalian HDPs
HDPs are short polypeptides, generally fewer than 50 amino acids, that display a wide range of in vitro antimicrobial activities against bacteria, fungi, viruses, and unicellular protozoa [21]. HDPs expressed in mammals are structurally diverse, predominantly expressed in leukocytes and epithelia [22,23,24], and nearly all were identified by in vitro antimicrobial screens of fractionated tissue extracts. A number of elegant studies have disclosed a central role for HDPs in innate immunity [25,26,27,28,29], thus it was logical that these molecules be evaluated for their potential as therapeutics. In addition, enzymatic cleavage of larger proteins may generate peptides (termed cryptides) with antimicrobial properties that potentially contribute to antimicrobial host defense [30]. Collectively, studies that began in the 1960s have identified several hundred antimicrobial peptides, many of which possess antifungal activities [18,31]. As discussed below, the vast majority of mammalian antifungal HDPs are fungicidal. Moreover, many HDPs also have immunoregulatory properties that appear to be essential for antifungal responses of host cells in vitro and for antifungal efficacy in vivo. In the following sections, we detail the major classes of mammalian antifungal HDPs, the status of their development as therapeutic candidates, and discuss promising advances of HDP-inspired, antifungal peptidomimetics.

2.1. Histatins
Histatins (Hsts; Table 3) constitute a family of linear histidine-rich cationic peptides isolated from human saliva [32]. Among the 12 Hst family members characterized, Hst5 is the most potent fungicidal peptide against C. albicans in vitro [33]. Synthetic Hst5 variants, termed Dhar4 and Dhar5, also inhibit biofilm formation of MDR C. albicans in vitro [34,35]. The candidacidal activity of Hst5 results from its binding to the yeast cell surface followed by internalization into the cytosol. Intracellular Hst5 induces oxidative stress and impairs mitochondrial function that induces a lethal ionic imbalance in fungal cells [33]. PAC-113 is a dodecapeptide, corresponding to amino acids 4–15 of Hst5, in which the C-terminal His is carboxamidated. Topically applied PAC-113 has been shown to be effective in phase I and II in clinical trials for oral candidiasis in HIV patients [18], and a rinse formulation for treatment and prevention of oral candidiasis is being developed by Pacgen Biopharmaceuticals. PAC-113 is currently marketed as an over-the-counter product in Taiwan. As topical agents, Hst and derivatives thereof have shown promise as candidacidal agents with low toxicity toward mammalian cells [36]. There have been no reports of systemic delivery of Hsts or their derivatives, indicating their utility is limited to topical applications.

2.2. Cathelicidins
The cathelicidin peptide family is a heterogeneous group of peptides with sizes ranging from 12 to 80 residues with highly diverse sequences and structures [73]. They share a highly conserved, amino terminal prepro sequence termed the cathelin domain. The most extensively studied antifungal cathelicidin is LL-37 (Table 3), the only known human cathelicidin. LL-37 is a cationic α-helical peptide composed of 37 amino acids that is widely expressed in the skin, gastrointestinal, urinary, and respiratory tracts [74,75], as well as by monocytes, neutrophils, NK, B, and T cells [76,77,78]. LL-37 is fungicidal in vitro against C. albicans and Aspergillus spp. [39,79]. LL-37 disrupts the cytoplasmic membrane of C. albicans blastospores [39] and also protects mammalian host cells by inhibiting biofilm formation and host cell binding by interaction with yeast cell wall carbohydrates [80]. LL-37 inhibits A. fumigatus hyphal growth and adhesion to host cells resulting in suppression of TNF-α and IL-6 release [42,45]. The immunoregulatory effects of LL-37 include its chemoattraction of neutrophils [38] and augmentation of reactive oxygen species (ROS) production by neutrophils exposed to phorbol 12-myristate 13-acetate or bacteria [37]. The peptide also induces chemokine release by leukocytes and epithelial cells, in particular IL-8, to increase neutrophil recruitment [40], and it inhibits neutrophil apoptosis [43]. LL-37 selectively modulates proinflammatory cytokines by peripheral blood mononuclear cells (PBMCs). For example, the peptide downregulates TNFα, IL-1β, IL-6, and IL-8 secretion by blood monocytes stimulated with TLR2 or TLR4 agonists, but it stimulates TNFα and IL-6 production by CpG-stimulated monocytes [20,41,44].

Other cathelicidins evaluated for their antifungal potential include porcine protegrins (cationic hairpin peptides of 16–18 amino acids stabilized by two disulfides) [46] and bovine indolicidin, a cationic tryptophan-rich tridecapeptide amide [81] (Table 3). Protegrins and indolicidin are expressed at high levels in granulocytes of the respective species. Protegrins have potent fungicidal activity against C. albicans in vitro but failed to advance clinically due to their unacceptable toxicity toward mammalian cells [46]. Similarly, indolicidin was fungicidal against Candida spp. and C. neoformans in vitro [82], but was cytotoxic and poorly tolerated in naive BALB/c mice that received the peptide i.v. [47]. However, liposomal encapsulation of indolicidin markedly reduced cytotoxicity and greatly improved tolerability when administered i.v. to mice [47]. This improved formulation was tested for therapeutic efficacy in mice challenged with A. fumigatus spores. A single dose of liposomal indolicidin was therapeutically effective in this model, providing evidence that liposomal formulation technology, used to enhance tolerability and efficacy of AmpB, could be applied to an antifungal peptide [47].

2.3. α- and β-Defensins
The defensin family comprises three structural subfamilies, termed α-, β-, and θ-defensins [83], the first two of which will be discussed here. α- and β-defensins vary in length from 29 to 47 amino acids [84], and despite having different tri-disulfide motifs, have remarkably similar tertiary structures (Table 3). In vitro, neutrophil α-defensins are fungicidal against numerous species, including C. albicans [85], C. neoformans [86], Coccidioides immitis [87], Rhizopus oryzae, and A. fumigatus [88]. Additionally, numerous studies demonstrate that human α-defensins possess immunomodulatory properties that are predominantly proinflammatory. For example, α-defensins induce IL-6 secretion by T-cells [50], upregulate TNFα and IL-1β expression by monocytes [48], stimulate TNFα, IL-6, and IL-12 expression in myeloid dendritic cells [89], and induce IL-8 release by lung epithelial cells [49,51,90]. α-defensins also act as a bridge between innate and acquired immunity by promoting antigen or tumor-specific immune responses in vitro and in vivo [50,91,92], mobilizing immature dendritic cells and naïve T lymphocytes [93], and enhancing chemotaxis of macrophages, mast cells, and T lymphocytes [94].

β-defensins were first identified in cattle [95,96], and soon thereafter discovered in humans [97]. There are more than 40 human β-defensin (HBD) genes [98], but most studies on HBD peptides have focused on HBDs 1–3 which are expressed in many tissues [99]. HBD-2 and 3 expression is induced by proinflammatory signals, such as TNFα and IL-1β [100,101,102,103,104,105], whereas HBD-1 is expressed constitutively [106,107]. HBD-1 was fungistatic against Candida spp. [108,109] whereas both HBD-2 and HBD-3 were fungicidal against C. albicans [55]. In addition to their microbicidal properties, like α-defensins, β-defensins function as immunostimulants. For example, mouse β-defensin-2 is an endogenous ligand for TLR-4 on immature dendritic cells, producing a Th1 polarized immune response with production of IL-1 α/β, IL-6, and IL-12 [52]. HBDs 2–4 induced expression of several proinflammatory cytokines in keratinocytes [53,54] and HBD-2 elicited similar effects in CD3/28-stimulated peripheral T-cells [53]. Under some conditions, HBDs are reported to have immunosuppressive activities [110].

Therapeutic development of α- and β-defensins, including those expressed in humans, have not advanced to the clinic for any indication. In fact, none of the antifungal peptides described above have been translated clinically for treatment of invasive mycoses. However, Hst and indolicidin analogs, LL-37-derived peptides, and a number of other synthetic peptides are under development as topical agents to treat a number infectious diseases including mucocutaneous candidiasis [31]. As discussed by Haney et al., it is not surprising that the antimicrobial activities of HDPs determined in vitro do not predictably translate functionally in the physiologic milieu of infected host tissues [111], despite the wide use of this approach for small molecules. For HDPs, the challenge of in vitro-to-in vivo translation, especially for a systemically administered drug, is complicated by other factors including unpredictable binding of the peptide to blood elements and tissues, peptide degradation, unfavorable pharmacokinetics, and potentially adverse effects of the HDP itself. It is evident, therefore, that preclinical efficacy and toxicology studies are required to justify clinical development of HDPs.

3. Potential Role of HDPs in Antifungal Drug Development
For reasons outlined above, the track record of peptide-based drug development of anti-infectives is littered with failures. Ironically, the development of peptide drugs in general is on a steep positive trajectory, with 20 new peptide-based clinical trials every year, and more than 400 peptidic drugs in clinical development. Over the last 20 years, a total of 60 peptide drugs have been approved worldwide, with metabolic disorders and cancer as the main targeted therapeutic areas [112]. Moreover, as noted above, a number of HDPs are in development for topical antifungal applications, including the treatment of oral and vulvovaginal candidiasis [31]. Despite the challenges of antifungal drug development in general, and the inherent barriers encountered in developing peptide drugs, there is reason to be hopeful that the biological properties of HDPs may contribute to the quest for new antifungal agents. The following sections provide a few examples of recent successes, exploiting both the antifungal and immunotherapeutic properties of HDPs.

3.1. IDR-1018
Hancock and colleagues were among the first to recognize that the antimicrobial efficacy of HDPs was linked to the immunoregulatory properties of the molecule [111,113]. This informed the synthesis of innate defense regulator (IDR) peptides using bovine cathelicidin Bac2a as the template for analog design and subsequent activity screens. Freitas et al. demonstrated the utility of this approach in studies of IDR-1018, a linear dodecapeptide amide that was tested for its effect on survival in a mouse model of systemic candidiasis [56]. Candidemic mice were treated daily with 1, 5, or 10 mg/kg of IDR-1018 by the i.p. route beginning 24 h post retroorbital infection. The highest dose statistically prolonged survival and had a modest effect on fungal kidney burden after 7 days of peptide treatment. It was concluded that the therapeutic effect of IDR-1018 is mediated by its modulation of proinflammatory cytokines (TNFα, IL-1β, IL-6, and IL-12) by bone marrow derived macrophages stimulated with heat killed C. albicans [56].

3.2. hLF 1-11
Human lactoferrin (hLF) is a 77 kDa iron-binding glycoprotein implicated in host defense by direct killing of C. albicans, or through the action of proteolytic fragments (cryptides). A number of studies were performed using hLF1-11, the amino terminal undecapeptide of hLF. hLF1-11 is fungicidal in vitro, having greater potency than hLF itself [59]. Direct fungal killing occurred by increasing mitochondrial potential and permeability via calcium uptake, which resulted in ROS and adenosine triphosphate production, and consequently in C. albicans cell death [58]. The efficacy of hLF1-11 in vivo was evaluated in neutropenic mice challenged i.v. with C. albicans Y01-19 and treated with a single i.v. dose of hLF1-11 24 h post infection. After an additional 18 h, mice were euthanized and renal fungal burden was quantified as a function of peptide dose. Significant reduction is fungal burden was obtained with peptide doses as low as 0.4 ng/kg [58]. Although the study design did not allow for determination of treatment impact on survival, histologic analysis indicated that peptide treatment inhibited filamentation of surviving fungi. Moreover, hLF1-11 treatment dose-dependently reduced serum TNFα and IL-6 in infected mice.

3.3. θ-Defensins
Recent studies suggest that θ-defensins, the third of the three mammalian defensin subfamilies, may represent a unique HDP template for antifungal drug development. θ-Defensins are cyclic octadecapeptides expressed exclusively in Old World monkeys and are the only known cyclic polypeptides in the Animal Kingdom [114]. The cyclic backbone is produced by head-to-tail splicing of two nonapeptides derived from α-defensin-like precursors [115], and binary combinations produce multiple θ-defensin isoforms (e.g., six in rhesus macaques [116]; 10 in olive baboons [117]) that have distinct antimicrobial activities against bacteria and fungi in vitro [9,116,117,118].

Rhesus theta defensin 1 (RTD-1), the first θ-defensin isoform described, has served as the prototype for characterizing in vitro antimicrobial activities against bacteria, fungi, and enveloped viruses [9,85,117,118,119,120,121,122]. In early in vivo studies, single dose administration of RTD-1 was effective in E. coli- and polymicrobial sepsis in BALB/c mice [62]. While RTD-1 is broadly microbicidal in vitro, numerous lines of evidence suggested that in vivo efficacy is a function of RTD-1 immunomodulation of systemic inflammation. Studies show that RTD-1 homeostatically regulates LPS- and E. coli-stimulated release of TNFα by inhibiting tumor necrosis alpha converting enzyme (TACE; ADAM17) [61], as well as other proinflammatory cytokines by regulation of nuclear factor kappa B and mitogen-activated protein kinase pathways [64]. These studies suggested that RTD-1 promotes survival in mouse models of sepsis by immunomodulation of the host response.

In a recent study, the candidacidal properties and fungicidal mechanisms of natural θ-defensin isoforms were evaluated, demonstrating that the peptides are broadly, though differentially, fungicidal against numerous Candida species including MDR resistant strains of C. albicans and C. auris [9]. RTD-1 killing of C. albicans was time and concentration dependent, and temporally correlated with yeast permeabilization, ATP release, and induction of fungal ROS [9]. RTD-1 was >200-fold more active than Hst5 in these studies, and was stable to fungal proteases that rapidly degraded Hst5 [9]. These findings are consistent with previous studies demonstrating the stability of RTD-1 in biological matrices [62]. Moreover, θ-defensins are extremely poor immunogens [63], suggesting that they, or analogs thereof, might have utility as systemically administered therapeutics.

Since RTD-1 was among the most potent and broadly anti-candidal θ-defensins in vitro [9], this peptide was evaluated for therapeutic efficacy in a mouse model of systemic candidiasis. Mice were challenged i.v. with drug sensitive or MDR C. albicans, and treated i.p. with 5 mg/kg of RTD-1 once daily for 7 days beginning 24 post infection [60]. RTD-1 was highly effective in promoting long term survival of mice infected with both C. albicans strains, and this was statistically equivalent to the effects of fluconazole and caspofungin in mice infected with drug sensitive C. albicans SC5314 [60]. In mice infected with MDR C. albicans 53264, endpoint analysis showed RTD-1 to be superior to both fluconazole and caspofungin [60]. In both infections, RTD-1 was highly effective in promoting fungal clearance, as determined by quantitation of renal fungal burden, and was more effective in promoting fungal clearance than fluconazole or caspofungin [60]. Moreover, RTD-1 treatment homeostatically restored dysregulated inflammatory responses, including chronically elevated granulocyte counts and inflammatory cytokines responses (TNFα, IL-1β, IL-6, IL-10, and IL-17) that occurred in sham-treated infected mice [60]. Interestingly, RTD-1 treatment produced a transient 3–4-fold increase in peripheral blood neutrophils in infected animals [60]. This may be significant given the importance of neutrophils in the host response to systemic fungal infection.

Analysis of pharmacokinetic parameters in RTD-1 treated mice revealed that the maximum plasma concentrations achieved in the multiple i.p. dosing scheme employed were less than 1% of that required to kill either organism in the presence of 50% mouse serum [60]. These data demonstrate that the effect of RTD-1 in resolving systemic candidiasis is not the result of direct fungal killing, but rather peptide-mediated augmentation of the host antifungal response. While the mechanistic details underlying the observed efficacy in vivo have yet to be revealed, a common feature of RTD-1 in multiple models is the modulation of dysregulated inflammation. This effect has been obtained in RTD-1 treatment of endotoxin-mediated lung injury [123], P. aeruginosa lung infection [119,124], and pulmonary inflammation in a murine model of SARS coronavirus infection [65]. These data suggest that cyclic θ-defensins represent a novel approach for developing HDPs as host directed agents that enhance the host response to fungal infection.

3.4. Immunomodulatory Peptides
The concept of host directed immunomodulation for treatment of infection has gained attention in recent years. Two examples are immunotherapeutic peptides, Raltecimod™ and Zadaxin™, both of which regulate systemic inflammation in the host. RaltecimodTM (AB103) developed by Atox Bio, is a CD28 mimetic that antagonizes CD28 cell signaling [66,67]. It is efficacious in mouse models of toxic shock, sepsis, and Gram negative bacterial peritonitis by promoting bacterial clearance and preventing septic shock. ZadaxinTM is a synthetic version of the 28 amino acid human peptide thymosin α 1. The peptide regulates multiple immune cell subsets by stimulating the production of cytokines and has been approved in 35 countries for treatment of hepatitis B and C and also shows promise for treatment of severe sepsis [68,69,70].

3.5. Antifungal Peptide Mimics
A promising approach, circumventing limitations of HDPs per se, has been the design and evaluation of HDP mimetics [71,125,126]. These nonpeptidic molecules, based on a meta-phenylene ethynylene core [127], a peptide mimic inspired by membrane binding properties of the frog skin peptide magainin II [128]. One analog, compound C4 (Table 3) was shown to permeabilize C. albicans yeast and hyphal cell membranes, inducing ATP release and propidium iodide uptake [71]. Further, C4 was fungicidal in vitro and in vivo and was highly efficacious in promoting long term survival of immunosuppressed mice challenged with C. albicans SC5314. Importantly, initial toxicity studies showed that C4 and related compounds have low in vitro and in vivo toxicities, demonstrating selectivity of a new class of antifungals [126].

4. Conclusions and Future Perspectives
Despite warnings of emerging MDR fungal pathogens, such as C. auris, only recently have there been significant national and international efforts devoted to antimicrobial resistance, only a fraction of which has been focused on systemic mycoses. Nevertheless, pockets of the scientific community are employing novel strategies to develop the next class of antifungal agents and novel therapeutic approaches. In this regard, peptide mimetics certainly hold promise. Further, there is growing evidence that HDP-inspired peptides that augment the host antifungal response and modulate dysregulated inflammation will contribute to the list of possible therapeutic solutions urgently required. Given the remarkable increase of peptides entering clinical trials in recent years (https://webs.iiitd.edu.in/raghava/thpdb/index.html), there is reason to be optimistic that peptides and peptide mimics will contribute to a much needed expansion of the clinical anti-infective armamentarium.

Acknowledgments
The authors would like to thank Vasu Punj for bioinformatics assistance in generating peptide structures in Table 3.

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author Contributions
V.B., D.Q.T., A.J.O., and M.E.S. wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding
V.B., D.Q.T., A.J.O., and M.E.S. were supported in by grants from National Institute of Allergy and Infectious Diseases grants (RO1 AI22931, RO1 AI125141, R44 AI142959), the Southern California Clinical and Translational Science Institute (UL1 TR000130), and National Cancer Institute (P30 CA014089). D.Q.T. receives salary support from Oryn Therapeutics, LLC.

Conflicts of Interest
M.E.S. is a founder and equity holder in Oryn Therapeutics, LLC. A.J.O and D.Q.T. hold equity in Oryn Therapeutics.

jof-06-00241-t001_Table 1Table 1 Annual worldwide fungal infections.

Fungal Disease	Estimated Cases	Mortality Rate	References	
Candidiasis	400,000/year	10–75%	[1,2,4]	
Aspergillosis	200,000/year	30–95%	[1,4]	
Cryptococcosis	1,000,000/year	20–70%	[1,4]	
jof-06-00241-t002_Table 2Table 2 Approved antifungals for clinical usage.

Antifungal Class	Fungal Targets	Mechanism of Action	Limitation	References	
Azoles	
Aspergillus, Candida, Cryptococcus
	Interference with ergosterol biosynthesis via 14α-demethylase inhibition	Fungistatic	[4,5]	
Polyenes	
Aspergillus, Candida, Cryptococcus, Histoplasma, Blastomyces
	Ergosterol extraction from plasma membrane	Toxicity	[4]	
Echinocandins	
Aspergillus, Candida
	β-1,3-glucan synthase inhibition	Poor oral bioavailability	[7]	
jof-06-00241-t003_Table 3Table 3 Representative host defense peptides (HDPs) and mimics.

Compound	Sequence/Structure	Structural Motif	Activity	Reference/Database	
Hst5
(histatin)	

	α-helix	Internalized after binding to fungal cell wall. Induces oxidative stress, affects ionic balance and mitochondrial function	Chemspider: 17289075
[33]	
LL-37
(human cathelicidin)	

	α-helix	Disrupts fungal membrane and modulates host responses in vitro	PDB: 2K6O
[20,37,38,39,40,41,42,43,44,45]	
Protegrin
(porcine cathelicidin)	

	Cysteine-rich β-sheet, two disulfide bridges	Fungicidal in vitro, cytotoxic and hemolytic to mammalian cells 	PDB: 1PG1
[46]	
Indolicidin
(bovine cathelicidin)	

	Extended chain containing five tryptophans	Antifungal activity, toxic in mammals	PDB:1G89
[47]	
HNP-1
(α-defensin)	

	Tri-disulfide stabilized β-sheet dominated monomers that from non-covalent dimers	Fungicidal in vitro, modulates host responses in vivo 	PDBE: 3hj2
[48,49,50,51]	
HBD-2
(β-defensin)	

	Tri-disulfide stabilized monomers that from non-covalent dimers	Fungicidal in vitro, modulates host responses in vivo	PDB:1FD4
[52,53,54,55]	
IDR-1018
(bactenecin derivative)	

	α-helix	Modulates cytokines in bone marrow-derived macrophages stimulated with heat-killed C. albicans	[56,57]	
hLF1-11
(human lactoferrin cryptide)	

	First 11 N-terminal amino acids of the human lactoferrin loop peptide	Fungicidal in vitro, inhibits C. albicans filamentation and reduces TNFα and IL-6 in vivo	[58,59]	
RTD-1
(θ-defensin)	

	Tri-disulfide β-stranded macrocycle	Permeabilizes fungal cells and induces oxidative stress in vitro, enhances fungal clearance in vivo	PDB: 2LYF
[9,60,61,62,63,64,65]	
AB103;
Raltecimod
(CD-28 mimetic)	

	D-Ala1, D-Ala10 CD-28 mimetic 	Modulates host responses in vivo 	Chemspider: 58828035
[66,67]	
Zadaxin	

	α-helix; synthetic version of human peptide thymosin α 1	Modulates host responses in vivo	PDB: 2L9I
[68,69,70]	
C4;
Compound 4
(mPE-derived)	

	Peptidomimetic derived from the magainin-inspired mPE	Disrupt fungal cell membrane in vitro, fungicidal in oral and systemic candidiasis in vivo	[71,72]
==== Refs
References
1. Brown G.D.  Denning D.W.  Gow N.A.  Levitz S.M.  Netea M.G.  White T.C.   Hidden killers: Human fungal infections Sci. Transl. Med. 2012 4 165rv113 10.1126/scitranslmed.3004404 23253612 
2. Pfaller M.A.  Diekema D.J.   Epidemiology of invasive candidiasis: A persistent public health problem Clin. Microbiol. Rev. 2007 20 133 163 10.1128/CMR.00029-06 17223626 
3. Yapar N.   Epidemiology and risk factors for invasive candidiasis Ther. Clin. Risk Manag. 2014 10 95 105 10.2147/TCRM.S40160 24611015 
4. Pianalto K.M.  Alspaugh J.A.   New Horizons in Antifungal Therapy J. Fungi 2016 2 26 10.3390/jof2040026 29376943 
5. Robbins N.  Wright G.D.  Cowen L.E.   Antifungal Drugs: The Current Armamentarium and Development of New Agents Microbiol. Spectr. 2016 4 10.1128/microbiolspec.FUNK-0002-2016 
6. Deray G.   Amphotericin B nephrotoxicity J. Antimicrob. Chemother. 2002 49 Suppl. 1 37 41 10.1093/jac/49.suppl_1.37 11801579 
7. Denning D.W.   Echinocandin antifungal drugs Lancet 2003 362 1142 1151 10.1016/S0140-6736(03)14472-8 14550704 
8. Eschenauer G.  Depestel D.D.  Carver P.L.   Comparison of echinocandin antifungals Ther. Clin. Risk Manag. 2007 3 71 97 10.2147/tcrm.2007.3.1.71 18360617 
9. Basso V.  Garcia A.  Tran D.Q.  Schaal J.B.  Tran P.  Ngole D.  Aqeel Y.  Tongaonkar P.  Ouellette A.J.  Selsted M.E.   Fungicidal Potency and Mechanisms of theta-Defensins against Multidrug-Resistant Candida Species Antimicrob. Agents Chemother. 2018 62 10.1128/AAC.00111-18 
10. Howard S.J.  Cerar D.  Anderson M.J.  Albarrag A.  Fisher M.C.  Pasqualotto A.C.  Laverdiere M.  Arendrup M.C.  Perlin D.S.  Denning D.W.   Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure Emerg. Infect. Dis. 2009 15 1068 1076 10.3201/eid1507.090043 19624922 
11. Pfaller M.A.   Antifungal drug resistance: Mechanisms, epidemiology, and consequences for treatment Am. J. Med. 2012 125 S3 S13 10.1016/j.amjmed.2011.11.001 22196207 
12. Pfaller M.A.  Messer S.A.  Boyken L.  Rice C.  Tendolkar S.  Hollis R.J.  Doern G.V.  Diekema D.J.   Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004) J. Clin. Microbiol. 2005 43 2163 2167 10.1128/JCM.43.5.2163-2167.2005 15872236 
13. Walker L.A.  Gow N.A.  Munro C.A.   Fungal echinocandin resistance Fungal Genet. Biol. 2010 47 117 126 10.1016/j.fgb.2009.09.003 19770064 
14. Navalkele B.D.  Revankar S.  Chandrasekar P.   Candida auris: A worrisome, globally emerging pathogen Expert Rev. Anti Infect. Ther. 2017 15 819 827 10.1080/14787210.2017.1364992 28783385 
15. Spivak E.S.  Hanson K.E.   Candida auris: An Emerging Fungal Pathogen J. Clin. Microbiol. 2018 56 10.1128/JCM.01588-17 
16. Clark C.  Drummond R.A.   The Hidden Cost of Modern Medical Interventions: How Medical Advances Have Shaped the Prevalence of Human Fungal Disease Pathogens 2019 8 45 10.3390/pathogens8020045 30987351 
17. Benedict K.  Jackson B.R.  Chiller T.  Beer K.D.   Estimation of Direct Healthcare Costs of Fungal Diseases in the United States Clin. Infect. Dis. 2019 68 1791 1797 10.1093/cid/ciy776 30204844 
18. Ciociola T.  Giovati L.  Conti S.  Magliani W.  Santinoli C.  Polonelli L.   Natural and synthetic peptides with antifungal activity Future Med. Chem. 2016 8 1413 1433 10.4155/fmc-2016-0035 27502155 
19. BR Da Silva L.  Taborda C.P.  Nosanchuk J.D.   Advances in Fungal Peptide Vaccines J. Fungi 2020 6 119 10.3390/jof6030119 
20. Mookherjee N.  Brown K.L.  Bowdish D.M.  Doria S.  Falsafi R.  Hokamp K.  Roche F.M.  Mu R.  Doho G.H.  Pistolic J.    Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37 J. Immunol. 2006 176 2455 2464 10.4049/jimmunol.176.4.2455 16456005 
21. Zasloff M.   Antimicrobial peptides of multicellular organisms Nature 2002 415 389 395 10.1038/415389a 11807545 
22. Boman H.G.   Peptide antibiotics and their role in innate immunity Annu. Rev. Immunol. 1995 13 61 92 10.1146/annurev.iy.13.040195.000425 7612236 
23. Selsted M.E.  Brown D.M.  DeLange R.J.  Harwig S.S.  Lehrer R.I.   Primary structures of six antimicrobial peptides of rabbit peritoneal neutrophils J. Biol. Chem. 1985 260 4579 4584 3988726 
24. Selsted M.E.  Szklarek D.  Lehrer R.I.   Purification and antibacterial activity of antimicrobial peptides of rabbit granulocytes Infect. Immun. 1984 45 150 154 10.1128/IAI.45.1.150-154.1984 6735465 
25. Chu H.  Pazgier M.  Jung G.  Nuccio S.P.  Castillo P.A.  de Jong M.F.  Winter M.G.  Winter S.E.  Wehkamp J.  Shen B.    Human alpha-defensin 6 promotes mucosal innate immunity through self-assembled peptide nanonets Science 2012 337 477 481 10.1126/science.1218831 22722251 
26. Lemaitre B.  Nicolas E.  Michaut L.  Reichhart J.M.  Hoffmann J.A.   The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults Cell 1996 86 973 983 10.1016/S0092-8674(00)80172-5 8808632 
27. Nizet V.  Ohtake T.  Lauth X.  Trowbridge J.  Rudisill J.  Dorschner R.A.  Pestonjamasp V.  Piraino J.  Huttner K.  Gallo R.L.   Innate antimicrobial peptide protects the skin from invasive bacterial infection Nature 2001 414 454 457 10.1038/35106587 11719807 
28. Salzman N.H.  Ghosh D.  Huttner K.M.  Paterson Y.  Bevins C.L.   Protection against enteric salmonellosis in transgenic mice expressing a human intestinal defensin Nature 2003 422 522 526 10.1038/nature01520 12660734 
29. Wilson C.L.  Ouellette A.J.  Satchell D.P.  Ayabe T.  Lopez-Boado Y.S.  Stratman J.L.  Hultgren S.J.  Matrisian L.M.  Parks W.C.   Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense Science 1999 286 113 117 10.1126/science.286.5437.113 10506557 
30. Samir P.  Link A.J.   Analyzing the cryptome: Uncovering secret sequences AAPS J. 2011 13 152 158 10.1208/s12248-011-9252-2 21327597 
31. Mookherjee N.  Anderson M.A.  Haagsman H.P.  Davidson D.J.   Antimicrobial host defence peptides: Functions and clinical potential Nat. Rev. Drug Discov. 2020 19 311 332 10.1038/s41573-019-0058-8 32107480 
32. Kavanagh K.  Dowd S.   Histatins: Antimicrobial peptides with therapeutic potential J. Pharm. Pharmacol. 2004 56 285 289 10.1211/0022357022971 15025852 
33. Puri S.  Edgerton M.   How does it kill?: Understanding the candidacidal mechanism of salivary histatin 5 Eukaryot. Cell 2014 13 958 964 10.1128/EC.00095-14 24951439 
34. De Prijck K.  De Smet N.  Rymarczyk-Machal M.  Van Driessche G.  Devreese B.  Coenye T.  Schacht E.  Nelis H.J.   Candida albicans biofilm formation on peptide functionalized polydimethylsiloxane Biofouling 2010 26 269 275 10.1080/08927010903501908 20054722 
35. Pusateri C.R.  Monaco E.A.  Edgerton M.   Sensitivity of Candida albicans biofilm cells grown on denture acrylic to antifungal proteins and chlorhexidine Arch. Oral Biol. 2009 54 588 594 10.1016/j.archoralbio.2009.01.016 19249746 
36. Zhu J.  Luther P.W.  Leng Q.  Mixson A.J.   Synthetic histidine-rich peptides inhibit Candida species and other fungi in vitro: Role of endocytosis and treatment implications Antimicrob. Agents Chemother. 2006 50 2797 2805 10.1128/AAC.00411-06 16870774 
37. Alalwani S.M.  Sierigk J.  Herr C.  Pinkenburg O.  Gallo R.  Vogelmeier C.  Bals R.   The antimicrobial peptide LL-37 modulates the inflammatory and host defense response of human neutrophils Eur. J. Immunol. 2010 40 1118 1126 10.1002/eji.200939275 20140902 
38. Ciornei C.D.  Sigurdardottir T.  Schmidtchen A.  Bodelsson M.   Antimicrobial and chemoattractant activity, lipopolysaccharide neutralization, cytotoxicity, and inhibition by serum of analogs of human cathelicidin LL-37 Antimicrob. Agents Chemother. 2005 49 2845 2850 10.1128/AAC.49.7.2845-2850.2005 15980359 
39. den Hertog A.L.  van Marle J.  van Veen H.A.  Van’t Hof W.  Bolscher J.G.  Veerman E.C.  Nieuw Amerongen A.V.   Candidacidal effects of two antimicrobial peptides: Histatin 5 causes small membrane defects, but LL-37 causes massive disruption of the cell membrane Biochem. J. 2005 388 689 695 10.1042/BJ20042099 15707390 
40. Filewod N.C.  Pistolic J.  Hancock R.E.   Low concentrations of LL-37 alter IL-8 production by keratinocytes and bronchial epithelial cells in response to proinflammatory stimuli FEMS Immunol. Med. Microbiol. 2009 56 233 240 10.1111/j.1574-695X.2009.00571.x 19527294 
41. Kai-Larsen Y.  Agerberth B.   The role of the multifunctional peptide LL-37 in host defense Front. Biosci. 2008 13 3760 3767 10.2741/2964 18508470 
42. Luo X.L.  Li J.X.  Huang H.R.  Duan J.L.  Dai R.X.  Tao R.J.  Yang L.  Hou J.Y.  Jia X.M.  Xu J.F.   LL37 Inhibits Aspergillus fumigatus Infection via Directly Binding to the Fungus and Preventing Excessive Inflammation Front. Immunol. 2019 10 283 10.3389/fimmu.2019.00283 30842778 
43. Nagaoka I.  Tamura H.  Hirata M.   An antimicrobial cathelicidin peptide, human CAP18/LL-37, suppresses neutrophil apoptosis via the activation of formyl-peptide receptor-like 1 and P2X7 J. Immunol. 2006 176 3044 3052 10.4049/jimmunol.176.5.3044 16493063 
44. Niyonsaba F.  Ushio H.  Nagaoka I.  Okumura K.  Ogawa H.   The human beta-defensins (-1, -2, -3, -4) and cathelicidin LL-37 induce IL-18 secretion through p38 and ERK MAPK activation in primary human keratinocytes J. Immunol. 2005 175 1776 1784 10.4049/jimmunol.175.3.1776 16034119 
45. Zhang Y.  Jiang Y.  Sun C.  Wang Q.  Yang Z.  Pan X.  Zhu M.  Xiao W.   The human cathelicidin LL-37 enhances airway mucus production in chronic obstructive pulmonary disease Biochem. Biophys. Res. Commun. 2014 443 103 109 10.1016/j.bbrc.2013.11.074 24291709 
46. Paredes-Gamero E.J.  Martins M.N.  Cappabianco F.A.  Ide J.S.  Miranda A.   Characterization of dual effects induced by antimicrobial peptides: Regulated cell death or membrane disruption Biochim. Biophys. Acta 2012 1820 1062 1072 10.1016/j.bbagen.2012.02.015 22425533 
47. Ahmad I.  Perkins W.R.  Lupan D.M.  Selsted M.E.  Janoff A.S.   Liposomal entrapment of the neutrophil-derived peptide indolicidin endows it with in vivo antifungal activity Biochim. Biophys. Acta 1995 1237 109 114 10.1016/0005-2736(95)00087-J 7632702 
48. Chaly Y.V.  Paleolog E.M.  Kolesnikova T.S.  Tikhonov I.I.  Petratchenko E.V.  Voitenok N.N.   Neutrophil alpha-defensin human neutrophil peptide modulates cytokine production in human monocytes and adhesion molecule expression in endothelial cells Eur. Cytokine Netw. 2000 11 257 266 10903805 
49. Khine A.A.  Del Sorbo L.  Vaschetto R.  Voglis S.  Tullis E.  Slutsky A.S.  Downey G.P.  Zhang H.   Human neutrophil peptides induce interleukin-8 production through the P2Y6 signaling pathway Blood 2006 107 2936 2942 10.1182/blood-2005-06-2314 16322472 
50. Lillard J.W. Jr.  Boyaka P.N.  Chertov O.  Oppenheim J.J.  McGhee J.R.   Mechanisms for induction of acquired host immunity by neutrophil peptide defensins Proc. Natl. Acad. Sci. USA 1999 96 651 656 10.1073/pnas.96.2.651 9892688 
51. Syeda F.  Liu H.Y.  Tullis E.  Liu M.  Slutsky A.S.  Zhang H.   Differential signaling mechanisms of HNP-induced IL-8 production in human lung epithelial cells and monocytes J. Cell. Physiol. 2008 214 820 827 10.1002/jcp.21279 17786963 
52. Biragyn A.  Ruffini P.A.  Leifer C.A.  Klyushnenkova E.  Shakhov A.  Chertov O.  Shirakawa A.K.  Farber J.M.  Segal D.M.  Oppenheim J.J.    Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2 Science 2002 298 1025 1029 10.1126/science.1075565 12411706 
53. Kanda N.  Kamata M.  Tada Y.  Ishikawa T.  Sato S.  Watanabe S.   Human β-defensin-2 enhances IFN-γ and IL-10 production and suppresses IL-17 production in T cells J. Leukoc. Biol. 2011 89 935 944 10.1189/jlb.0111004 21367976 
54. Niyonsaba F.  Ushio H.  Nakano N.  Ng W.  Sayama K.  Hashimoto K.  Nagaoka I.  Okumura K.  Ogawa H.   Antimicrobial peptides human beta-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines J. Investig. Dermatol. 2007 127 594 604 10.1038/sj.jid.5700599 17068477 
55. Vylkova S.  Nayyar N.  Li W.  Edgerton M.   Human beta-defensins kill Candida albicans in an energy-dependent and salt-sensitive manner without causing membrane disruption Antimicrob. Agents Chemother. 2007 51 154 161 10.1128/AAC.00478-06 17074797 
56. Freitas C.G.  Lima S.M.F.  Freire M.S.  Cantuaria A.P.C.  Junior N.G.O.  Santos T.S.  Folha J.S.  Ribeiro S.M.  Dias S.C.  Rezende T.M.B.    An Immunomodulatory Peptide Confers Protection in an Experimental Candidemia Murine Model Antimicrob. Agents Chemother. 2017 61 10.1128/AAC.02518-16 28559266 
57. Wieczorek M.  Jenssen H.  Kindrachuk J.  Scott W.R.  Elliott M.  Hilpert K.  Cheng J.T.  Hancock R.E.  Straus S.K.   Structural studies of a peptide with immune modulating and direct antimicrobial activity Chem. Biol. 2010 17 970 980 10.1016/j.chembiol.2010.07.007 20851346 
58. Lupetti A.  Brouwer C.P.  Bogaards S.J.  Welling M.M.  de Heer E.  Campa M.  van Dissel J.T.  Friesen R.H.  Nibbering P.H.   Human lactoferrin-derived peptide’s antifungal activities against disseminated Candida albicans infection J. Infect. Dis. 2007 196 1416 1424 10.1086/522427 17922408 
59. Lupetti A.  Paulusma-Annema A.  Welling M.M.  Senesi S.  van Dissel J.T.  Nibbering P.H.   Candidacidal activities of human lactoferrin peptides derived from the N terminus Antimicrob. Agents Chemother. 2000 44 3257 3263 10.1128/AAC.44.12.3257-3263.2000 11083624 
60. Basso V.  Tran D.Q.  Schaal J.B.  Tran P.  Eriguchi Y.  Ngole D.  Cabebe A.E.  Park A.Y.  Beringer P.M.  Ouellette A.J.    Rhesus Theta Defensin 1 Promotes Long Term Survival in Systemic Candidiasis by Host Directed Mechanisms Sci. Rep. 2019 9 16905 10.1038/s41598-019-53402-z 31729441 
61. Schaal J.B.  Maretzky T.  Tran D.Q.  Tran P.A.  Tongaonkar P.  Blobel C.P.  Ouellette A.J.  Selsted M.E.   Macrocyclic theta-defensins suppress tumor necrosis factor-alpha (TNF-alpha) shedding by inhibition of TNF-alpha-converting enzyme J. Biol. Chem. 2018 293 2725 2734 10.1074/jbc.RA117.000793 29317500 
62. Schaal J.B.  Tran D.  Tran P.  Osapay G.  Trinh K.  Roberts K.D.  Brasky K.M.  Tongaonkar P.  Ouellette A.J.  Selsted M.E.   Rhesus macaque theta defensins suppress inflammatory cytokines and enhance survival in mouse models of bacteremic sepsis PLoS ONE 2012 7 e51337 10.1371/journal.pone.0051337 23236475 
63. Schaal J.B.  Tran D.Q.  Subramanian A.  Patel R.  Laragione T.  Roberts K.D.  Trinh K.  Tongaonkar P.  Tran P.A.  Minond D.    Suppression and resolution of autoimmune arthritis by rhesus theta-defensin-1, an immunomodulatory macrocyclic peptide PLoS ONE 2017 12 e0187868 10.1371/journal.pone.0187868 29145473 
64. Tongaonkar P.  Trinh K.K.  Schaal J.B.  Tran D.  Gulko P.S.  Ouellette A.J.  Selsted M.E.   Rhesus macaque theta-defensin RTD-1 inhibits proinflammatory cytokine secretion and gene expression by inhibiting the activation of NF-kappaB and MAPK pathways J. Leukoc. Biol. 2015 98 1061 1070 10.1189/jlb.3A0315-102R 26269197 
65. Wohlford-Lenane C.L.  Meyerholz D.K.  Perlman S.  Zhou H.  Tran D.  Selsted M.E.  McCray P.B. Jr.   Rhesus theta-defensin prevents death in a mouse model of severe acute respiratory syndrome coronavirus pulmonary disease J. Virol. 2009 83 11385 11390 10.1128/JVI.01363-09 19710146 
66. Ramachandran G.  Kaempfer R.  Chung C.S.  Shirvan A.  Chahin A.B.  Palardy J.E.  Parejo N.A.  Chen Y.  Whitford M.  Arad G.    CD28 homodimer interface mimetic peptide acts as a preventive and therapeutic agent in models of severe bacterial sepsis and gram-negative bacterial peritonitis J. Infect. Dis. 2015 211 995 1003 10.1093/infdis/jiu556 25305323 
67. Ramachandran G.  Tulapurkar M.E.  Harris K.M.  Arad G.  Shirvan A.  Shemesh R.  Detolla L.J.  Benazzi C.  Opal S.M.  Kaempfer R.    A peptide antagonist of CD28 signaling attenuates toxic shock and necrotizing soft-tissue infection induced by Streptococcus pyogenes J. Infect. Dis. 2013 207 1869 1877 10.1093/infdis/jit104 23493729 
68. Camerini R.  Garaci E.   Historical review of thymosin alpha 1 in infectious diseases Expert Opin. Biol. Ther. 2015 15 Suppl. 1 S117 S127 10.1517/14712598.2015.1033393 26098768 
69. King R.  Tuthill C.   Immune Modulation with Thymosin Alpha 1 Treatment Vitam. Horm. 2016 102 151 178 10.1016/bs.vh.2016.04.003 27450734 
70. Pei F.  Guan X.  Wu J.   Thymosin alpha 1 treatment for patients with sepsis Expert Opin. Biol. Ther. 2018 18 71 76 10.1080/14712598.2018.1484104 30063866 
71. Menzel L.P.  Chowdhury H.M.  Masso-Silva J.A.  Ruddick W.  Falkovsky K.  Vorona R.  Malsbary A.  Cherabuddi K.  Ryan L.K.  DiFranco K.M.    Potent in vitro and in vivo antifungal activity of a small molecule host defense peptide mimic through a membrane-active mechanism Sci. Rep. 2017 7 4353 10.1038/s41598-017-04462-6 28659617 
72. Ryan L.K.  Freeman K.B.  Masso-Silva J.A.  Falkovsky K.  Aloyouny A.  Markowitz K.  Hise A.G.  Fatahzadeh M.  Scott R.W.  Diamond G.   Activity of potent and selective host defense peptide mimetics in mouse models of oral candidiasis Antimicrob. Agents Chemother. 2014 58 3820 3827 10.1128/AAC.02649-13 24752272 
73. Zanetti M.   Cathelicidins, multifunctional peptides of the innate immunity J. Leukoc. Biol. 2004 75 39 48 10.1189/jlb.0403147 12960280 
74. Frohm M.  Agerberth B.  Ahangari G.  Stahle-Backdahl M.  Liden S.  Wigzell H.  Gudmundsson G.H.   The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders J. Biol. Chem. 1997 272 15258 15263 10.1074/jbc.272.24.15258 9182550 
75. Bals R.   Epithelial antimicrobial peptides in host defense against infection Respir. Res. 2000 1 141 150 10.1186/rr25 11667978 
76. Agerberth B.  Charo J.  Werr J.  Olsson B.  Idali F.  Lindbom L.  Kiessling R.  Jornvall H.  Wigzell H.  Gudmundsson G.H.   The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations Blood 2000 96 3086 3093 10.1182/blood.V96.9.3086 11049988 
77. Gudmundsson G.H.  Agerberth B.  Odeberg J.  Bergman T.  Olsson B.  Salcedo R.   The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes Eur. J. Biochem. 1996 238 325 332 10.1111/j.1432-1033.1996.0325z.x 8681941 
78. Kahlenberg J.M.  Kaplan M.J.   Little peptide, big effects: The role of LL-37 in inflammation and autoimmune disease J. Immunol. 2013 191 4895 4901 10.4049/jimmunol.1302005 24185823 
79. Mania D.  Hilpert K.  Ruden S.  Fischer R.  Takeshita N.   Screening for antifungal peptides and their modes of action in Aspergillus nidulans Appl. Environ. Microbiol. 2010 76 7102 7108 10.1128/AEM.01560-10 20833782 
80. Tsai P.W.  Yang C.Y.  Chang H.T.  Lan C.Y.   Human antimicrobial peptide LL-37 inhibits adhesion of Candida albicans by interacting with yeast cell-wall carbohydrates PLoS ONE 2011 6 e17755 10.1371/journal.pone.0017755 21448240 
81. Selsted M.E.  Novotny M.J.  Morris W.L.  Tang Y.Q.  Smith W.  Cullor J.S.   Indolicidin, a novel bactericidal tridecapeptide amide from neutrophils J. Biol. Chem. 1992 267 4292 4295 1537821 
82. van Abel R.J.  Tang Y.Q.  Rao V.S.  Dobbs C.H.  Tran D.  Barany G.  Selsted M.E.   Synthesis and characterization of indolicidin, a tryptophan-rich antimicrobial peptide from bovine neutrophils Int. J. Pept. Protein Res. 1995 45 401 409 10.1111/j.1399-3011.1995.tb01055.x 7591479 
83. Selsted M.E.   A pocket guide to explorations of the defensin field Curr. Pharm. Des. 2007 13 3061 3064 10.2174/138161207782110363 17979748 
84. Selsted M.E.  Ouellette A.J.   Mammalian defensins in the antimicrobial immune response Nat. Immunol. 2005 6 551 557 10.1038/ni1206 15908936 
85. Lehrer R.I.  Ganz T.  Szklarek D.  Selsted M.E.   Modulation of the in vitro candidacidal activity of human neutrophil defensins by target cell metabolism and divalent cations J. Clin. Investig. 1988 81 1829 1835 10.1172/JCI113527 3290255 
86. Alcouloumre M.S.  Ghannoum M.A.  Ibrahim A.S.  Selsted M.E.  Edwards J.E. Jr.   Fungicidal properties of defensin NP-1 and activity against Cryptococcus neoformans in vitro Antimicrob. Agents Chemother. 1993 37 2628 2632 10.1128/AAC.37.12.2628 8109927 
87. Segal G.P.  Lehrer R.I.  Selsted M.E.   In vitro effect of phagocyte cationic peptides on Coccidioides immitis J. Infect. Dis. 1985 151 890 894 10.1093/infdis/151.5.890 3989323 
88. Levitz S.M.  Selsted M.E.  Ganz T.  Lehrer R.I.  Diamond R.D.   In vitro killing of spores and hyphae of Aspergillus fumigatus and Rhizopus oryzae by rabbit neutrophil cationic peptides and bronchoalveolar macrophages J. Infect. Dis. 1986 154 483 489 10.1093/infdis/154.3.483 3525696 
89. Presicce P.  Giannelli S.  Taddeo A.  Villa M.L.  Della Bella S.   Human defensins activate monocyte-derived dendritic cells, promote the production of proinflammatory cytokines, and up-regulate the surface expression of CD91 J. Leukoc. Biol. 2009 86 941 948 10.1189/jlb.0708412 19477909 
90. Van Wetering S.  Mannesse-Lazeroms S.P.  Van Sterkenburg M.A.  Daha M.R.  Dijkman J.H.  Hiemstra P.S.   Effect of defensins on interleukin-8 synthesis in airway epithelial cells Am. J. Physiol. 1997 272 L888 L896 10.1152/ajplung.1997.272.5.L888 9176253 
91. Brogden K.A.  Ackermann M.  McCray P.B. Jr.  Tack B.F.   Antimicrobial peptides in animals and their role in host defences Int. J. Antimicrob. Agents 2003 22 465 478 10.1016/S0924-8579(03)00180-8 14602364 
92. Tani K.  Murphy W.J.  Chertov O.  Salcedo R.  Koh C.Y.  Utsunomiya I.  Funakoshi S.  Asai O.  Herrmann S.H.  Wang J.M.    Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigens Int. Immunol. 2000 12 691 700 10.1093/intimm/12.5.691 10784615 
93. Yang D.  Chen Q.  Chertov O.  Oppenheim J.J.   Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells J. Leukoc. Biol. 2000 68 9 14 10914484 
94. Grigat J.  Soruri A.  Forssmann U.  Riggert J.  Zwirner J.   Chemoattraction of macrophages, T lymphocytes, and mast cells is evolutionarily conserved within the human alpha-defensin family J. Immunol. 2007 179 3958 3965 10.4049/jimmunol.179.6.3958 17785833 
95. Diamond G.  Zasloff M.  Eck H.  Brasseur M.  Maloy W.L.  Bevins C.L.   Tracheal antimicrobial peptide, a cysteine-rich peptide from mammalian tracheal mucosa: Peptide isolation and cloning of a cDNA Proc. Natl. Acad. Sci. USA 1991 88 3952 3956 10.1073/pnas.88.9.3952 2023943 
96. Selsted M.E.  Tang Y.Q.  Morris W.L.  McGuire P.A.  Novotny M.J.  Smith W.  Henschen A.H.  Cullor J.S.   Purification, primary structures, and antibacterial activities of beta-defensins, a new family of antimicrobial peptides from bovine neutrophils J. Biol. Chem. 1993 268 6641 6648 8454635 
97. Lehrer R.I.   Primate defensins Nat. Rev. Microbiol. 2004 2 727 738 10.1038/nrmicro976 15372083 
98. Meade K.G.  O’Farrelly C.   beta-Defensins: Farming the Microbiome for Homeostasis and Health Front. Immunol. 2018 9 3072 10.3389/fimmu.2018.03072 30761155 
99. Garcia J.R.  Krause A.  Schulz S.  Rodriguez-Jimenez F.J.  Kluver E.  Adermann K.  Forssmann U.  Frimpong-Boateng A.  Bals R.  Forssmann W.G.   Human beta-defensin 4: A novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity FASEB J. 2001 15 1819 1821 10.1096/fj.00-0865fje 11481241 
100. Diamond G.  Russell J.P.  Bevins C.L.   Inducible expression of an antibiotic peptide gene in lipopolysaccharide-challenged tracheal epithelial cells Proc. Natl. Acad. Sci. USA 1996 93 5156 5160 10.1073/pnas.93.10.5156 8643545 
101. Jia H.P.  Schutte B.C.  Schudy A.  Linzmeier R.  Guthmiller J.M.  Johnson G.K.  Tack B.F.  Mitros J.P.  Rosenthal A.  Ganz T.    Discovery of new human beta-defensins using a genomics-based approach Gene 2001 263 211 218 10.1016/s0378-1119(00)00569-2 11223260 
102. Russell J.P.  Diamond G.  Tarver A.P.  Scanlin T.F.  Bevins C.L.   Coordinate induction of two antibiotic genes in tracheal epithelial cells exposed to the inflammatory mediators lipopolysaccharide and tumor necrosis factor alpha Infect. Immun. 1996 64 1565 1568 10.1128/IAI.64.5.1565-1568.1996 8613361 
103. Schroder J.M.  Harder J.   Human beta-defensin-2 Int. J. Biochem. Cell Biol. 1999 31 645 651 10.1016/S1357-2725(99)00013-8 10404637 
104. Singh P.K.  Jia H.P.  Wiles K.  Hesselberth J.  Liu L.  Conway B.A.  Greenberg E.P.  Valore E.V.  Welsh M.J.  Ganz T.    Production of beta-defensins by human airway epithelia Proc. Natl. Acad. Sci. USA 1998 95 14961 14966 10.1073/pnas.95.25.14961 9843998 
105. Zasloff M.   Inducing endogenous antimicrobial peptides to battle infections Proc. Natl. Acad. Sci. USA 2006 103 8913 8914 10.1073/pnas.0603508103 16754884 
106. Shi J.  Zhang G.  Wu H.  Ross C.  Blecha F.  Ganz T.   Porcine epithelial beta-defensin 1 is expressed in the dorsal tongue at antimicrobial concentrations Infect. Immun. 1999 67 3121 3127 10.1128/IAI.67.6.3121-3127.1999 10338529 
107. Valore E.V.  Park C.H.  Quayle A.J.  Wiles K.R.  McCray P.B. Jr.  Ganz T.   Human beta-defensin-1: An antimicrobial peptide of urogenital tissues J. Clin. Investig. 1998 101 1633 1642 10.1172/JCI1861 9541493 
108. Joly S.  Maze C.  McCray P.B. Jr.  Guthmiller J.M.   Human beta-defensins 2 and 3 demonstrate strain-selective activity against oral microorganisms J. Clin. Microbiol. 2004 42 1024 1029 10.1128/JCM.42.3.1024-1029.2004 15004048 
109. Krishnakumari V.  Rangaraj N.  Nagaraj R.   Antifungal activities of human beta-defensins HBD-1 to HBD-3 and their C-terminal analogs Phd1 to Phd3 Antimicrob. Agents Chemother. 2009 53 256 260 10.1128/AAC.00470-08 18809937 
110. Semple F.  Webb S.  Li H.N.  Patel H.B.  Perretti M.  Jackson I.J.  Gray M.  Davidson D.J.  Dorin J.R.   Human beta-defensin 3 has immunosuppressive activity in vitro and in vivo Eur. J. Immunol. 2010 40 1073 1078 10.1002/eji.200940041 20104491 
111. Haney E.F.  Straus S.K.  Hancock R.E.W.   Reassessing the Host Defense Peptide Landscape Front. Chem. 2019 7 43 10.3389/fchem.2019.00043 30778385 
112. Lee A.C.  Harris J.L.  Khanna K.K.  Hong J.H.   A Comprehensive Review on Current Advances in Peptide Drug Development and Design Int. J. Mol. Sci. 2019 20 2383 10.3390/ijms20102383 31091705 
113. Mansour S.C.  Pena O.M.  Hancock R.E.   Host defense peptides: Front-line immunomodulators Trends Immunol. 2014 35 443 450 10.1016/j.it.2014.07.004 25113635 
114. Lehrer R.I.  Cole A.M.  Selsted M.E.   theta-Defensins: Cyclic peptides with endless potential J. Biol. Chem. 2012 287 27014 27019 10.1074/jbc.R112.346098 22700960 
115. Tang Y.Q.  Yuan J.  Osapay G.  Osapay K.  Tran D.  Miller C.J.  Ouellette A.J.  Selsted M.E.   A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated alpha-defensins Science 1999 286 498 502 10.1126/science.286.5439.498 10521339 
116. Tongaonkar P.  Tran P.  Roberts K.  Schaal J.  Osapay G.  Tran D.  Ouellette A.J.  Selsted M.E.   Rhesus macaque theta-defensin isoforms: Expression, antimicrobial activities, and demonstration of a prominent role in neutrophil granule microbicidal activities J. Leukoc. Biol. 2011 89 283 290 10.1189/jlb.0910535 21084627 
117. Garcia A.E.  Osapay G.  Tran P.A.  Yuan J.  Selsted M.E.   Isolation, synthesis, and antimicrobial activities of naturally occurring theta-defensin isoforms from baboon leukocytes Infect. Immun. 2008 76 5883 5891 10.1128/IAI.01100-08 18852242 
118. Tran D.  Tran P.  Roberts K.  Osapay G.  Schaal J.  Ouellette A.  Selsted M.E.   Microbicidal properties and cytocidal selectivity of rhesus macaque theta defensins Antimicrob. Agents Chemother. 2008 52 944 953 10.1128/AAC.01090-07 18160518 
119. Beringer P.M.  Bensman T.J.  Ho H.  Agnello M.  Denovel N.  Nguyen A.  Wong-Beringer A.  She R.  Tran D.Q.  Moskowitz S.M.    Rhesus theta-defensin-1 (RTD-1) exhibits in vitro and in vivo activity against cystic fibrosis strains of Pseudomonas aeruginosa J. Antimicrob. Chemother. 2016 71 181 188 10.1093/jac/dkv301 26433781 
120. Brandt C.R.  Akkarawongsa R.  Altmann S.  Jose G.  Kolb A.W.  Waring A.J.  Lehrer R.I.   Evaluation of a theta-defensin in a Murine model of herpes simplex virus type 1 keratitis Investig. Ophthalmol. Vis. Sci. 2007 48 5118 5124 10.1167/iovs.07-0302 17962464 
121. Seidel A.  Ye Y.  de Armas L.R.  Soto M.  Yarosh W.  Marcsisin R.A.  Tran D.  Selsted M.E.  Camerini D.   Cyclic and acyclic defensins inhibit human immunodeficiency virus type-1 replication by different mechanisms PLoS ONE 2010 5 e9737 10.1371/journal.pone.0009737 20305815 
122. Yasin B.  Wang W.  Pang M.  Cheshenko N.  Hong T.  Waring A.J.  Herold B.C.  Wagar E.A.  Lehrer R.I.   Theta defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry J. Virol. 2004 78 5147 5156 10.1128/JVI.78.10.5147-5156.2004 15113897 
123. Jayne J.G.  Bensman T.J.  Schaal J.B.  Park A.Y.J.  Kimura E.  Tran D.  Selsted M.E.  Beringer P.M.   Rhesus Theta (theta)-Defensin-1 Attenuates Endotoxin-Induced Acute Lung Injury by Inhibiting Proinflammatory Cytokines and Neutrophil Recruitment Am. J. Respir. Cell Mol. Biol. 2017 10.1165/rcmb.2016-0428OC 
124. Bensman T.J.  Jayne J.G.  Sun M.  Kimura E.  Meinert J.  Wang J.C.  Schaal J.B.  Tran D.  Rao A.P.  Akbari O.    Efficacy of Rhesus Theta-Defensin-1 in Experimental Models of Pseudomonas aeruginosa Lung Infection and Inflammation Antimicrob. Agents Chemother. 2017 61 10.1128/AAC.00154-17 
125. Scott R.W.  Tew G.N.   Mimics of Host Defense Proteins; Strategies for Translation to Therapeutic Applications Curr. Top. Med. Chem. 2017 17 576 589 10.2174/1568026616666160713130452 27411325 
126. Chowdhury M.H.  Ryan L.K.  Cherabuddi K.  Freeman K.B.  Weaver D.G.  Pelletier J.C.  Scott R.W.  Diamond G.   Antifungal Potential of Host Defense Peptide Mimetics in a Mouse Model of Disseminated Candidiasis J. Fungi 2018 4 30 10.3390/jof4010030 
127. Beckloff N.  Laube D.  Castro T.  Furgang D.  Park S.  Perlin D.  Clements D.  Tang H.  Scott R.W.  Tew G.N.    Activity of an antimicrobial peptide mimetic against planktonic and biofilm cultures of oral pathogens Antimicrob. Agents Chemother. 2007 51 4125 4132 10.1128/AAC.00208-07 17785509 
128. Zasloff M.   Magainins, a class of antimicrobial peptides from Xenopus skin: Isolation, characterization of two active forms, and partial cDNA sequence of a precursor Proc. Natl. Acad. Sci. USA 1987 84 5449 5453 10.1073/pnas.84.15.5449 3299384